Literature DB >> 27163573

Predictive factors for Leishmania infantum infection in dogs examined at a veterinary teaching hospital in Teresina, State of Piauí, Brazil.

Marcus Vinicius Gouvêa1, Ivete Lopes Mendonça2, Maria do Socorro Pires E Cruz3, Carlos Henrique Nery Costa4, José Ueleres Braga1, Guilherme Loureiro Werneck1.   

Abstract

INTRODUCTION: In Brazil, culling of seropositive dogs is one of the recommended strategies to control visceral leishmaniasis. Since infectiousness is correlated with clinical signs, control measures targeting symptomatic dogs could be more effective.
METHODS: A cross-sectional study was carried out among 1,410 dogs, predictive models were developed based on clinical signs and an indirect immunofluorescence antibody test.
RESULTS: The validated predictive model showed sensitivity and specificity of 86.5% and 70.0%, respectively.
CONCLUSIONS: Predictive models could be used as tools to aid control programs in focusing on a smaller fraction of dogs contributing more to infection dissemination.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27163573     DOI: 10.1590/0037-8682-0187-2015

Source DB:  PubMed          Journal:  Rev Soc Bras Med Trop        ISSN: 0037-8682            Impact factor:   1.581


  2 in total

1.  Scoring clinical signs can help diagnose canine visceral leishmaniasis in a highly endemic area in Brazil.

Authors:  Kleverton Ribeiro da Silva; Vitor Rosa Ramos de Mendonça; Kellen Matuzzy Silva; Leopoldo Fabrício Marçal do Nascimento; Antonio Ferreira Mendes-Sousa; Flaviane Alves de Pinho; Manoel Barral-Netto; Aldina Maria Prado Barral; Maria do Socorro Pires E Cruz
Journal:  Mem Inst Oswaldo Cruz       Date:  2017-01-01       Impact factor: 2.743

2.  A cross-sectional approach including dog owner characteristics as predictors of visceral leishmaniasis infection in dogs.

Authors:  Ana Izabel Passarella Teixeira; Debora Marcolino Silva; Lúcia Rolim Santana de Freitas; Gustavo Adolfo Sierra Romero
Journal:  Mem Inst Oswaldo Cruz       Date:  2020-04-27       Impact factor: 2.743

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.